KR20210095620A - 암 치료 방법 - Google Patents

암 치료 방법 Download PDF

Info

Publication number
KR20210095620A
KR20210095620A KR1020217011840A KR20217011840A KR20210095620A KR 20210095620 A KR20210095620 A KR 20210095620A KR 1020217011840 A KR1020217011840 A KR 1020217011840A KR 20217011840 A KR20217011840 A KR 20217011840A KR 20210095620 A KR20210095620 A KR 20210095620A
Authority
KR
South Korea
Prior art keywords
compound
formula
therapeutically effective
effective amount
cancer
Prior art date
Application number
KR1020217011840A
Other languages
English (en)
Korean (ko)
Inventor
마이크 사테크지
앨리슨 에이. 아르무어
리차드 메스만
Original Assignee
엔도사이트, 인코포레이티드
마이크 사테크지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔도사이트, 인코포레이티드, 마이크 사테크지 filed Critical 엔도사이트, 인코포레이티드
Publication of KR20210095620A publication Critical patent/KR20210095620A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020217011840A 2018-09-21 2019-09-20 암 치료 방법 KR20210095620A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734,649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (fr) 2018-09-21 2019-09-20 Méthodes de traitement de cancer

Publications (1)

Publication Number Publication Date
KR20210095620A true KR20210095620A (ko) 2021-08-02

Family

ID=69887889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011840A KR20210095620A (ko) 2018-09-21 2019-09-20 암 치료 방법

Country Status (9)

Country Link
US (1) US20220125957A1 (fr)
EP (1) EP3852816A4 (fr)
JP (1) JP2022501441A (fr)
KR (1) KR20210095620A (fr)
CN (1) CN113164631A (fr)
AU (1) AU2019345320A1 (fr)
CA (1) CA3112806A1 (fr)
IL (1) IL281600A (fr)
WO (1) WO2020061458A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
TW202216205A (zh) 2020-07-13 2022-05-01 加拿大商波因特生物製藥股份有限公司 放射性藥劑及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
MX2016005013A (es) * 2013-10-18 2017-02-28 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3400229B1 (fr) * 2016-01-10 2024-03-06 Provincial Health Services Authority Composés marqués au 18/19f qui ciblent l'antigène membranaire spécifique de la prostate
US10980901B2 (en) * 2016-12-15 2021-04-20 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of PMSA expressing cancers
AU2018382539B2 (en) * 2017-12-13 2024-07-11 Sciencons AS Complex comprising a PSMA-targeting compound linked to a lead or thorium radionuclide

Also Published As

Publication number Publication date
US20220125957A1 (en) 2022-04-28
EP3852816A1 (fr) 2021-07-28
WO2020061458A1 (fr) 2020-03-26
IL281600A (en) 2021-05-31
CN113164631A (zh) 2021-07-23
EP3852816A4 (fr) 2022-07-13
AU2019345320A1 (en) 2021-04-22
CA3112806A1 (fr) 2020-03-26
JP2022501441A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
US10172967B2 (en) Anticancer therapy
JP2024059640A (ja) 癌を治療する方法
JP2024028840A (ja) シールド剤およびそれらの使用
KR20210095620A (ko) 암 치료 방법
RU2825637C2 (ru) Способы лечения рака
RU2811406C2 (ru) Способы лечения рака
WO2017205447A1 (fr) Méthodes de traitement du cancer avec un composé ligand de psma-tubulysine
AU2006316781B2 (en) Therapy of malignant neoplasias
WO2023209122A1 (fr) Traitement combiné du cancer du poumon à petites cellules
KR20230123968A (ko) 치료진단제로 사용하기 위한 방사성 표지된 알파-v 베타-3 및/또는 알파-v 베타-5 인테그린 길항제
JP2023552383A (ja) ペプチド受容体放射性核種療法